Pharmaceuticals and Healthcare

RTI partners with Codetta Bio to boost healthcare innovation

RTI International has announced a strategic collaboration with Codetta Bio, a company specialising in multi-omics for precision medicine development, to fast-track healthcare innovation.

AstraZeneca targets $80bn revenue by 2030

AstraZeneca has announced an ambitious target to deliver total revenue of $80bn by 2030, an increase from $45.8bn in 2023.  

IMA Life to build new pharma freeze-drying equipment production site

IMA Life North America is set to establish a new $30m facility in Tonawanda, New York, US, aimed at increasing its production capabilities for pharmaceutical freeze-drying equipment.

Celltrion secures new public tenders for two biosimilars in Peru

Biopharmaceutical company Celltrion has solidified its presence in the Latin American pharmaceutical market with a series of successful public tender wins in Peru.

AcelRx Pharmaceuticals completes divestment of DSUVIA to Alora Pharmaceuticals

California-based AcelRx Pharmaceuticals has completed the divestment of DSUVIA to Alora Pharmaceuticals. 

GSK plans to spin off Consumer Healthcare unit

GlaxoSmithKline (GSK) has plans to spin off its Consumer Healthcare unit by demerging a minimum of 80% of the company’s 68% stake to its shareholders.

Xeris Pharmaceuticals to acquire Strongbridge Biopharma for $267m

US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m.

USFDA approves Janssen’s PONVORY for treatment of multiple sclerosis

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

USFDA extends review period for AbbVie’s sNDA of upadacitinib

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.